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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Diabetes är en sjukdom där patienterna inte kan använda sitt blodsocker på ett normalt sätt 
på grund av problem med hormonet insulin. Diabetiker delas upp i ungdomsdiabetiker (typ 1) 
och vuxendiabetiker (typ 2). Till skillnad från ungdomsdiabetiker som helt saknar insulin, kan  
vuxendiabetiker producera eget insulin. Normalt ger insulin en signal till musklerna att de skall 
ta upp socker från blodet efter en måltid. Hos vuxendiabetiker saknar insulinet verkan i 
musklerna, vilket brukar kallas att musklerna har blivit insulinresistenta. Då insulinsignaleringen 
inte fungerar kan socker inte tas upp av musklerna, och de drabbade får högt blodsocker som 
följd. Ny forskning har visat att musklernas insulinresistens uppkommer till följd av för mycket 
fett inne i musklerna. Fettet hindrar att blodsockret används. Det vore därför önskvärt att 
minska fettet inne i musklerna och hellre lagra det i fettvävnaden.  
 
Musklernas fettupptag har tidigare studerats grundligt. Däremot känner man inte till hur 
fetterna transporteras från blodcirkulationen igenom blodkärlen fram till musklerna. Man vet 
inte heller vad som reglerar blodkärlens fettupptag, eller vilka fettransportörer som är 
involverade. Denna avhandling visar att blodkärlen har en roll i fettupptaget, och att en 
minskning av blodkärlens fettupptag skyddar mot vuxendiabetes. 
 
Delarbete 1 beskriver blodkärlens roll i fettupptaget från blodcirkulationen till musklerna. 
Vi studerar ett protein som kallas VEGF-B, som produceras av musklerna och skickas av dessa 
till närliggande blodkärl. VEGF-Bs funktion har tidigare varit okänd. Vi visar att rollen för 
VEGF-B är att berätta för blodkärlen att musklerna behöver mer näring i form av fetter. På det 
sättet kan musklerna troligen få tillräcklig näring då de arbetar, och samtidigt skyddas mot för 
mycket fettupptag. Stimulering av blodkärl med VEGF-B ledde till att blodkärlen tillverkade fler 
fettransportörer, och därmed tog upp mer fetter. Då vi hämmade VEGF-B eller 
fettransportörerna upphörde fettupptaget. Vi studerade även en musstam som saknar VEGF-B 
(Vegfb-/- möss). Dessa möss hade lägre fettupptag till muskler och hjärta, och därmed även 
minskad ansamling av fett inne i musklerna. Istället tog Vegfb-/- mössen upp mer socker från 
blodcirkulationen. Sammanfattningsvis visar studien att VEGF-B kan kontrollera blodkärlens 
fettransport, och att inhibering av VEGF-B minskar mängden fett i musklerna. 
 
Delarbete 2 visar hur en begränsning av VEGF-B kan skydda mot utvecklingen av diabetes. 
För att studera diabetes hos möss använde vi oss av en musstam med möss som blir väldigt 
feta och parallellt utvecklar vuxendiabetes (db/db möss). Vi korsade db/db mössen med Vegfb-
/- mössen. Vi testade även att behandla db/db möss med en antikropp som binder till och 
hämmar VEGF-B. Både musstamskorsningen och antikroppsbehandlingen ledde till lägre 
fettinnehåll i hjärtmuskulaturen. Som följd av detta minskade insulinresistensen och db/db 
mössen började använda mer blodsocker. Dessutom visar vi att korrigering av insulinresistens 
i hjärta och muskler inte bara leder till lägre blodsocker, utan även till lägre blodfetter och 
bättre kolesterolvärden. Studien visar att utan VEGF-B fungerar blodkärlen som ett effektivt 
hinder mot alltför högt fettupptag till musklerna. Behandling med antikroppar som begränsar 
VEGF-B har därmed potential att minska insulinresistens och vuxendiabetes. 
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ABSTRACT 
 
The incidence of type 2 diabetes and the metabolic syndrome is rapidly increasing among both 
adults and children worldwide. Type 2 diabetes is strongly associated with obesity and ectopic 
lipid accumulation. Recent research has shown that peripheral insulin sensitivity is directly 
impaired by excessive lipid deposition within tissues. Therefore, it would be highly beneficial to 
be able to control lipid uptake and accumulation in organs prone to developing insulin 
resistance. The role of the vasculature as a controlling barrier for FA uptake has not 
previously been explored in detail. 
 
In Paper I, we describe an unexpected role for Vascular Endothelial Growth Factor B 
(VEGF-B) in the control and endothelial targeting of fatty acids to heart and muscle. VEGF-B 
signals in a paracrine fashion through its receptors present on vascular endothelial cells. We 
show that the expression of Vegfb is tightly co-regulated with the expression of nuclear-
encoded mitochondrial genes. VEGF-B signalling to the endothelium upregulates the mRNA 
and protein levels of Fatty Acid Transport Proteins (FATPs). Increased vascular FATP-levels 
leads to subsequent uptake and transport of long chain fatty acids across the endothelium. 
Mice lacking VEGF-B, or its receptors, have lower endothelial expression of FATPs and show 
less accumulation of lipid droplets within peripheral tissues. We conclude that VEGF-B is part 
of a novel regulatory mechanism, whereby endothelial lipid uptake and mitochondrial lipid 
usage is tightly coordinated.  
 
In Paper II, we show that inhibition of VEGF-B signalling protects against the development of 
insulin resistance in the db/db mouse model of type 2 diabetes. Genetic deletion of either one, 
or both, copies of Vegfb in db/db mice significantly reduces cardiac lipid deposition and leads to 
increased glucose usage. The db/db//vegfb-/- mice are protected against the development of 
hyperglycaemia, glucose intolerance and triglyceridemia. Pre-diabetic db/db mice receiving 
neutralising anti-VEGF-B antibodies similarly do not develop hyperglycaemia or triglyceridemia. 
Anti-VEGF-B treatment of mice with established diabetes prevents a further increase in blood 
glucose levels. The study shows that the endothelium can act as an efficient barrier against 
excessive nutrient uptake, even in a pathological context. Based on these results, we propose 
that targeting VEGF-B could be a future approach for treating peripheral insulin resistance and 
type 2 diabetes. 
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1 INTRODUCTION 
Blood vessels are the highways of the body, transporting nutrients and oxygen to the 
most distant tissues and cells. Oxygen is used during mitochondrial oxidative 
phosphorylation to convert the energy from the nutrients into energy-rich ATP that 
the cells can utilise. Although tissue oxygenation has been extensively studied by 
vascular biologists1,2 (Chapter I), little is known of the role of the vasculature in fatty 
acid (FA) transport and delivery3,4 (Figure 1 and Chapter 2). However, it has become 
clear that excessive delivery of nutrients to peripheral cells can be deleterious to 
cellular function, and cause metabolic dysfunction and related diseases5 (Chapter 3). 
 
New blood vessels are formed from existing ones through a process called 
angiogenesis. Members of the Vascular Endothelial Growth Factor (VEGF) family are 
crucial players in both developmental and adult physiological and pathological 
angiogenesis6. Therefore, it was highly unexpected that a member of the family, VEGF-
B, had a restricted angiogenic role7,8, and was not regulated by tissue hypoxia9.  
 
The discovery that VEGF-B has a role in FA delivery to peripheral tissues is the central 
theme of this thesis (Paper I). The work describes a novel biological role for a 
member of the VEGFs, and shows that the vasculature participates in both the 
regulation and delivery of FAs to the tissue. Moreover, inhibition of VEGF-B-mediated 
FA uptake in diabetic db/db mice protects the mice against the development of 
metabolic disease (Paper II). Based on our data, we propose that VEGF-B is part of a 
novel regulatory cycle, coordinating mitochondrial lipid usage to lipid uptake. In 
retrospective, it is not surprising that nature uses members of the VEGF family for 
efficient delivery of both oxygen and of nutrients to the tissues. 
 
Vascular metabolomics studies how vascular growth and endothelial cell (EC) physiology 
can impact the energy metabolism of the parenchymal cells (Chapter 4). Although this 
thesis focuses on the VEGFs and FA transporters, it will hopefully help to inspire 
additional new thinking around similar themes. Happy reading! 
 
Figure 1. Traditional view of FA transport. 
The major rate-limiting step in FA 
uptake was thought to occur at the 
muscle sarcolemma, whereas the 
endothelium did not impose a barrier 
for lipid transport. NEFAs, non-
esterified FAs  
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1.1 VEGFs IN HEALTH AND DISEASE  
“In my more grandiose moments, I think of a day to come when it may be possible to use 
angiogenesis inhibitors as an adjunct to conventional therapy” 
Judah Folkman, GHA Clowes Memorial Award Lecture 198610 
 
 
Vessels are formed as a primary vascular plexus through the process of vasculogenesis 
during early embryonic development11. The undifferentiated vessels undergo extensive 
angiogenic remodelling through growth, branching, sprouting and pruning, and form a 
mature organised network consisting of arteries, veins and capillaries. Although adult 
physiological angiogenesis is restricted, pathological angiogenesis is a key step in 
several disorders, most notably tumour development and macular degeneration in the 
retina6. Today pharmacological tools that inhibit pathological vessel growth have been 
developed12. Many of these tools target members of the VEGF family6,13,14. 
 
1.1.1 VEGF ligands and receptors 
The VEGF family of growth factors are key mediators of vasculogenesis and 
angiogenesis both during embryonic development and in adult physiology and 
pathology15-17. The family includes five mammalian ligands, VEGF-A, -B, -C, -D and 
Placental Growth Factor (PlGF), which all occur in different splice variants16. They bind 
in a partially overlapping pattern to three tyrosine kinase (TK) receptors, VEGF 
receptor-1, -2 and -3 (VEGFR1-3)15,17 (Figure 2). Co-receptors have been identified 
and include Neuropilin-1 and -2 (NRP1-2) and heparan sulphate proteoglycans 
(HSPs)15,18. The additional non-mammalian members of the VEGFs, found in 
parapoxvirus (VEGF-E) and snake venom (VEGF-F), will not be discussed within this 
thesis work6.  
 
The VEGF-ligands are secreted as ∼40 kDa large dimeric glycoproteins, which signal in 
a paracrine fashion to VEGFRs19,20. They preferentially form homodimers, but VEGF-
A/PlGF and VEGF-A/VEGF-B heterodimers have been isolated21,22. Binding of growth 
factors to their receptors is mediated by the VEGF-homology domain, consisting of 
eight conserved cysteine-residues15,23. Binding induces receptor dimerisation, and 
subsequent signalling inside the cell. All three VEGFRs are required for normal 
development, and knock-out mice lacking any of the receptors die prenatally15,23.  
 
 
VEGF-C and VEGF-D and VEGFR3 
VEGF-C, VEGF-D and VEGFR3 are all implicated in the formation and maintenance of 
lymph-endothelial vasculature23. Mice lacking one or both copies of Vegfc develop 
oedema, and Vegfc-/- and Vegfr3-/- mice die during development15,23. The Vegfd-/- mice are 
healthy and fertile15. These VEGFs will not be further discussed in this thesis.  
 
 
 
Vascular Metabolomics 
 3 
 
 
 
 
 
VEGF-A 
VEGF-A (also called Vascular Permeability Factor, VPF) is the major angiogenic factor. 
It binds to VEGFR1, VEGFR2 and the NRPs, but exerts its main angiogenic functions 
via VEGFR215,23. Its expression is strongly induced by hypoxia and Hypoxia Inducible 
Factor 1α (HIF1α)24. Vegfa expression is also regulated in a HIF-independent manner 
in response to nutrient deprivation25 (see Chapter 4). The various VEGF-A splice 
isoforms have different binding affinities to HSPs and thus different solubility26. This 
creates a VEGF-A gradient, which endothelial tip cells of the existing vasculature can 
sense and migrate towards27. VEGF-A is a potent permeability factor28, and a survival 
factor for the ECs29.  
 
VEGF-A is required for the development of the vascular system, as mice lacking even a 
single copy of the gene die in utero from defects in EC-development and vascular 
formation30,31. The highest Vegfa expression in the adult animal is found in heart, 
skeletal muscle and lung23. The expression of VEGF-A is also upregulated in most solid 
tumours, and in some other pathological conditions such as atherosclerosis, diabetic 
retinopathy and arthritis23.  
 
Several anti-angiogenic therapies targeting VEGF-A/VEGFR signalling have been 
developed12,13. The monoclonal antibody Bevacizumab (Avastin) that targets VEGF-A, as 
well as the TK-inhibitors Sunitinib (Sutent) and Sorafenib (Nexavar), have been US-FDA 
approved and are commonly used in the clinic for the treatment of several cancers13. 
All three drugs have multiple mechanisms of action including normalisation of the 
tumour vasculature and direct effects on the tumour cells13. Anti-VEGF-A therapy 
using Bevacizumab is also used for the treatment of proliferative diabetic 
retinopathy32,33.  
 
 
Figure 2. VEGF ligands and receptors. 
The five dimeric ligands bind to 
three receptors in a partially 
overlapping manner on endothelial 
cells (ECs) and lymphendothelial cells 
(LECs). Dashed line indicates that 
proteolytic cleavage is needed before 
receptor binding. Only ligand 
homodimers are shown. VEGF-B, 
PLGF and VEGF-A all bind NRP1 
(binding pattern not shown). 
Carolina Hagberg 
 4 
VEGF-B 
VEGF-B was discovered in Ulf Eriksson’s laboratory in 199621. The two splice 
isoforms, VEGF-B167 and VEGF-B186, differ in their C-terminal amino acid sequences
34, 
and show different diffusion properties and receptor-binding affinities34,35. Both 
isoforms bind specifically to VEGFR1 and NRP135,36. VEGF-B167 is the predominant 
form and binds to cell surface HSPs, making it less soluble37. VEGF-B186 is freely 
diffusible, but requires proteolytic cleavage before binding to NRP134. Both isoforms 
are expressed in adult tissues, with the highest expression in the myocardium, brown 
adipose tissue (BAT), skeletal muscle and pancreas34,37. During the development, Vegfb 
is expressed in the mouse heart and BAT, and the cardiac expression is strong already 
at day E8.520,38.  
 
The VEGF-B knock-out mice are healthy and fertile, and do not show vascular 
defects7,8. Moreover, the expression of VEGF-B is not induced by hypoxia, in contrast 
to all the other VEGF-ligands9,39. The angiogenic role of VEGF-B has been studied in 
the context of ischemic injury, pulmonary hypertension and retinopathy, but the 
results have been both disappointing and contradicting40-44. Cardiac overexpression of 
VEGF-B by adenoviral delivery induced heart-specific angiogenesis45,46, whereas genetic 
overexpression in the hearts of transgenic mice did not lead to any vascular changes47. 
The consensus is that VEGF-B has a restricted role in angiogenesis45-48.  
 
Instead, the overexpression of VEGF-B seems to robustly induce myocardial 
hypertrophy45,47,49,50. The molecular mechanism behind this remains unclear. The 
hypertrophy requires cardiac expression of VEGFR1, and could therefore involve 
paracrine signalling between ECs and cardiomyocytes45. Alternatively, it could be due 
to excess delivery of nutrients to the tissue, as mice overexpressing VEGF-B have 
increased cardiac ceramide accumulation23,47. The hypertrophy has been explained by 
expression of Vegfr1 on cardiomyocytes49,50, which is in contrary to previous 
reports19,51. It is important that the correct expression pattern of VEGFR1 is resolved, 
in order to fully understand the function of VEGF-B. Finally, it was shown that VEGF-B 
has anti-apoptotic effects on neurons in the brain and retina, by downregulating pro-
apoptotic proteins belonging to the BH3-only family52,53. In conclusion, the biological 
role of VEGF-B signalling to the endothelium has remained enigmatic due to 
contradictory results and the lack of identified endothelial downstream targets54.  
 
Placental Growth Factor (PlGF) 
PlGF is, similarly to VEGF-B, a VEGFR1-specific ligand, and can also bind to the 
NRPs55-57. Although PlGF is expressed at low levels in the healthy adult, its expression 
is strongly upregulated in different pathologies such as tumour growth and 
atherosclerosis14,58. PlGF stimulates vessel growth, either directly or by enhancing 
VEGF-A-driven angiogenesis (Figure 3), and it also recruits other pro-angiogenic cell 
types such as macrophages14,59. PlGF knock-out mice have no apparent morphological 
changes, but the mice show weaker tumour growth and delayed wound healing 
mechanisms, further supporting a pathological role for PlGF60-62. PlGF has therefore 
been considered as an ideal anti-angiogenic target for cancer treatment, and results 
from tumour-bearing mice receiving anti-PlGF antibodies initially looked very 
promising63-65. However, recently the efficiency of anti-PlGF treatment was questioned, 
and further research on the role of PlGF in vascular growth is needed66.  
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VEGFR1 and VEGFR2 
VEGFR2 (KDR or Flk-1) is the main angiogenic and vasculogenic VEGF-receptor15,23. 
Vegfr2 is expressed post-developmentally by proliferating ECs and tumour ECs and by 
neurons, but is downregulated in the quiescent endothelium15,67. VEGF-A binds directly 
to VEGFR2 and induces subsequent signalling through either PI3K or MAPK mediated 
pathways23. VEGF-C and VEGF-D can also bind to the VEGFR2 after proteolytic 
activation23. Interestingly, the affinity of VEGF-A is greater towards VEGFR1 then 
VEGFR215,17 (Figure 3).  
 
The role of VEGFR1 (Flt-1) in angiogenesis is less clear. Vegfr1 is expressed by ECs51, 
monocytes and macrophages, and in adults it is mainly involved in vascular 
permeability and inflammatory cell recruitment59,65. VEGFR1 is also produced as a 
secreted, soluble form (sVEGFR1), which can act as a trap for all its ligands during 
vessel growth, and in the placenta68. During development VEGFR1 seems to attenuate 
VEGF-A/VEGFR2 signalling by trapping VEGF-A (Figure 3)69. Vegfr1-/- embryos die early 
during development due to overgrowth and derangement of vessels69. On the 
contrary, deletion of only the intracellular TK-domain of VEGFR1 (VEGFR1-TK-/- 
mice) results in healthy and fertile mice, which have reduced transendothelial 
migration of macrophages70. Difficulties in detecting receptor phosphorylation in 
response to VEGF-A has added to the confusion around VEGFR115,23. This has lead to 
the “sink theory”, discussed on the next page.  
 
 
 
 
 
NRPs 
The NRPs were originally discovered as receptors for semaphorins, mediating 
repulsive signals during axonal guidance71. It was long thought that NRPs do not 
possess signalling capacity themselves. Recently the C-terminal tail of NRP1 was 
shown to bind to and signal via PDZ-domain containing proteins72. This will open up 
for novel interesting research, as focus has previously been on the detection of 
VEGFR-phosphorylation levels in response to ligand binding.  
 
 
Figure 3. Schematic drawing of the sink 
theory. A) VEGF-A has higher affinity 
for VEGFR1 then VEGFR2, which leads 
to trapping of VEGF-A, and attenuation 
of the VEGFR2-mediated angiogenic 
signal. B) PlGF indirectly stimulates 
pathological angiogenesis by displacing 
VEGF-A from VEGFR1, thereby 
enabling VEGF-A/VEGFR2 driven 
angiogenesis. 
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The NRPs have a wide expression pattern, and are found in both the nervous and the 
vascular systems15. NRP1 is expressed by the arterial vasculature, and also by many 
tissue cells such as cardiomyocytes and myocytes, whereas NRP2 is more prominently 
expressed by the venous and lymphatic endothelium15. Nrp1-/- mice die prenatally due 
to defective neuronal patterning and vessel formation73, whereas Nrp2-/- mice survive 
development but also have neuronal defects15,74,75.  
 
 
1.1.2 VEGFs: controversies and recent advances 
Although the angiogenic field has made several significant advances over the last ten 
years, there still exist some interesting unanswered questions.  
 
Ligand redundancy and specificity. How does a redundant ligand/receptor system manage 
to produce ligand specific signalling? The “holy grail” of the VEGF-field is still 
unresolved. PlGF and VEGF-A signalling have been shown to phosphorylate separate 
sets of tyrosine residues on VEGFR1, and thereby induce growth factor-specific 
downstream target genes60. It would be interesting to perform large-scale analysis 
comparing the transcriptional and post-transcriptional changes in response to all three 
VEGFR1 ligands, including VEGF-B. Specific co-receptors can be enough to induce 
ligand specific signalling. This has been shown for other redundant growth factor 
systems, namely the novel FGFs76. The discovery that NRP1 has signalling capacity 
might open for similar findings within the VEGF-family. NRP1 has been shown to, 
independently from VEGFR2, mediate VEGF-A-stimulated migration of ECs77. The 
identification of peptides or motifs important for binding NRP1 might lead to the 
identification of epitopes specific for each growth factor18,78.  
 
The sink theory revisited. According to the sink theory, the role of VEGFR1 is to 
attenuate VEGF-A/VEGFR2 signalling by trapping a portion of the secreted VEGF-A48 
(Figure 3A). The theory is based on the lack of angiogenic phenotype in the Vegfb-/- and 
VEGFR1-TK-/- mice, together with the strong binding affinity of VEGF-A to 
VEGFR17,8,60. In addition, part of the pathological angiogenic effect of PlGF stems from 
displacing VEGF-A from VEGFR1, thereby increasing VEGF-A/VEGFR2 signalling45 
(Figure 3B). However, evidence is now emerging in support of VEGFR1-specific 
downstream signalling45,52. Presently it is thought that VEGFR2 mediates angiogenesis 
in response to acute stimuli, and is downregulated in quiescent vasculature67. In 
contrary, VEGFR1 and its ligand VEGF-B instead mediate the basal physiological 
functions of the vasculature, such as macrophage transmigration across ECs and 
nutrient uptake47,59. Therefore the Vegfb-/- and VEGFR1-TK-/- mouse phenotypes are 
subtle48. In addition, the biological roles of VEGF-B, PlGF and VEGFR1 might also be 
disguised by other redundant systems with overlapping functions. 
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1.2 FATTY ACID UPTAKE AND TRANSPORT 
“Defining the mechanism(s) of LCFA movement through membranes is vital to understanding 
whether or not entry of FA into cells can be controlled at the plasma membrane of a typical cell”  
Hamilton, Guo and Kamp79 
 
Nutritional long-chain fatty acids (LCFAs) are delivered to peripheral tissues in two 
forms in the circulation, either as part of lipoprotein-associated triglycerides (TGs), or 
as albumin-bound non-esterified fatty acids (NEFAs). Lipoproteins are the major 
postprandial delivery route, whereas during fasting high circulating NEFA levels 
originate from lipolysis of the white adipose tissue (WAT). 
 
In short, chylomicrons deliver TGs to peripheral tissues directly from the intestine, 
whereas Very Low Density Lipoproteins (VLDLs) are assembled in the liver from both 
chylomicron-remnants and from endogenous lipids80,81. TGs from both of these 
lipoproteins are then hydrolyzed at the site of peripheral tissues through the action of 
vascular bound lipoprotein lipase (LPL), yielding NEFAs81. Lipoproteins can also be 
endocytosed via binding to lipoprotein receptors, which are not discussed here in 
detail. The subsequent transport of NEFAs across the endothelium has been poorly 
characterised3 as most research has been focused on sarcolemmal transport82,83 
(Figure 1). 
 
Originally, it was suggested that hydrophobic NEFAs could freely diffuse through the 
plasma membrane (PM) by a process called flip-flopping79. Today, we have ample 
evidence supporting the idea that protein-mediated FA uptake is the major route of 
entry of NEFAs into cells84. The cellular transport of NEFAs is saturable and substrate 
selective. Treatment of cells with proteases, which hydrolyse all extracellular proteins, 
inhibits cellular FA uptake. Furthermore, the working tissue needs to ensure lipid 
delivery when circulating NEFA levels are low, and limit uptake when they are high, 
thus demanding an active transport system. Three groups of proteins have been 
implicated in FA transport over the PM84: CD36, Fatty Acid Binding Proteins (FABPs) 
and the Fatty Acid Transport Proteins (FATPs)(Figure 3). Most genetic knock-out 
studies of these proteins have yielded healthy, viable mice despite defective FA 
accumulation84-86, supporting the existence of redundant pathways that rescue nutrient 
delivery.  
 
 
 
Figure 4. FA handling proteins. The FABPs are 
intracellular soluble proteins, whereas the 
FATPs are though to span the PM six times 
and CD36 has two transmembrane 
domains. FABPPM is associated to CD36 on 
the extracellular side. 
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1.2.1 Scavenging fatty acids: CD36  
CD36 (also called Fatty Acid Translocase, FAT) is an 88 kDa, heavily glycosylated 
scavenger (“cleaning”) receptor that belongs to an evolutionarily conserved protein 
family of scavengers87. CD36 recognises and binds to a large variety of lipids and lipid 
structures88,89, and its multiple functions have led to four different lines of CD36 
research. CD36 has a role in innate immunity as it recognizes bacterial lipid 
components, and participates in phagocytosis87,88,90. CD36 is also the endothelial 
receptor for mediating the anti-angiogenic signalling of thrombospondin-191,92. CD36 is 
well studied as a macrophage scavenger receptor for oxidized low-density lipoproteins 
(LDL), and has been attributed a role in atherosclerotic lesion formation93-95. 
Additionally CD36 is studied as a facilitator of physiological LCFA-transport96, which 
will be discussed here. 
 
Expression. Cd36 is expressed by platelets, monocytes, ECs and by parencymal cells in 
WAT, BAT, heart and skeletal muscle87,97. Its expression on ECs is still debated98-100. 
Importantly, Cd36 is strongly upregulated by the nuclear transcription factor 
Peroxisome-proliferator activated receptor gamma (PPARγ)93,101. Endothelial-specific 
deletion of PPARγ in mice ablated endothelial Cd36 expression, and in many aspects 
phenocopied the Cd36-/- mouse102 (see below). 
 
Peripheral LCFA-uptake. CD36 potently binds FAs and facilitates their uptake, although 
the detailed mechanism remains unknown and controversial103-107. CD36 localises to 
lipid rafts within the PM108, and the mechanism might involve vesicle formation, or 
CD36 might work in tandem with other FA handling proteins (Figure 6). CD36 is 
activated both in response to glucose109 and insulin110, suggesting a postprandial role 
for CD36 in lipid uptake. It has also been show that CD36 can bind native 
lipoproteins89 and participate in the clearance of chylomicron from the circulation111. In 
addition to mediating FA uptake in heart and muscle, CD36 is important for the 
intestinal absorption of nutritional fat111. For further discussion on this topic, see 
Chapter 4. 
 
Knockout studies. Cd36-/- mice are viable and fertile, but show lower intra-muscular TG 
contents and lower blood glucose, and have hypertriglyceridemia due to reduced FA 
uptake112,113. Muscle-specific overexpression of CD36 results in muscular lipid 
accumulation and lower plasma VLDL levels114. It was concluded that inhibition of 
CD36 was highly beneficial. However, in a subsequent study when the mice were fed 
either a high sucrose or a high fat diet (HFD), the Cd36-/- mice responded worse then 
wt mice, and developed insulin resistance (IR)115. This was probably because global 
CD36-deficiency also affects the WAT, leading to ectopic lipid accumulation in the 
liver and other non-CD36-dependent organs116 (see Chapter 3). Moreover, it was 
discovered that the Spontaneously Hypertensive Rat (SHR) acquires its phenotype due 
to a CD36 deficiency117,118. The SHR has been used as a model for a model for type 2 
diabetes (T2D), hypertriglyceridemia and defective lipolysis. The finding of numerous 
CD36 deficient patients, with symptoms ranging from T2D to cadiomyopathy, further 
strengthens the importance of adequate CD36 expression119,120. 
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Role of CD36 in WAT. Cd36-/- mice have defective FA uptake to the WAT and reduced 
fat mass112,113. The mice have constantly higher plasma TGs, whereas their NEFAs are 
only elevated during fasting, suggesting defective WAT-lipolysis and/or LPL-function 
instead of reduced NEFA uptake113. CD36 deficient SHR rats have larger adipocytes 
then control strains, suggesting that CD36 is not simply involved in adipocyte lipid 
accumulation117. Thus, CD36 has an important role in FA accumulation in WAT, 
although the mechanism remains unknown.  
 
PPARγ. The thiazolidinediones are PPARγ agonists that have been used as anti-diabetic 
drugs121. They are thought to induce PPARγ-mediated shunting of TGs from peripheral 
tissues to the WAT, thereby increasing peripheral insulin sensitivity122 (see Chapter 3). 
CD36 is upregulated by PPARγ104. As the thiazolidinediones therefore induce Cd36 
transcription, increased CD36 levels, especially in the WAT, should be beneficial. 
Exploring the consequences of CD36 overexpression in adipocytes or in the WAT 
vascular bed, and comparing the results to treatment with thiazolidinediones, would 
be extremely interesting. The association of both human and rodent CD36 deficiency 
with numerous pathologies123 indicates that proper CD36 expression is important, 
especially in the WAT, and further ideas of therapeutic inactivation of the protein 
should be limited124. 
 
 
1.2.2 Intracellular FA handling: the FABPs 
The FABPs consist of at least nine ∼15 kDa mammalian members with different 
expression patterns and biological functions125. They are soluble cytoplasmic proteins 
that traffic their ligands between various intracellular compartments. The most well 
studied FABPs are the adipose FABP (A-FABP or aP2), and the epidermal FABP (E-
FABP), which both also are expressed by ECs126 (Chapter 4). Most of the FABPs have 
been genetically deleted125. The genetic studies underline the idea that altered 
intracellular lipid distribution has major impacts on systemic metabolism. 
 
In contrast, the FABPPM (Got2 or mAspAt) does not belong to the same FABP family
84. 
It is larger (40 kDa) and associated with both the PM and CD36 on the extracellular 
side (Figure 4), and is also found in mitochondria84. Its primary role thus seems to be 
to assist CD36 in FA-handling84. 
 
 
1.2.3 The enigmatic FATPs 
The FATPs127 (Fatty Acid Transport Proteins or Slc27a-family) are a family of six 
mammalian proteins (FATP1-6) which transverse the PM several times128 (Figure 4). 
The 70-80 kDa large proteins are evolutionary conserved129 and expressed in a tissue- 
and/or cell type-specific manner86. However, their specific detection is difficult due to 
a high sequence similarity in their C-terminus, towards which most antibodies 
classically are made (AF, unpublished observation). Their mechanism of FA transport 
is not known, although it has been proposed that FATP1-dimers can form a pore 
through the PM130,131.  
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The FATPs have an intracellular (Very) Long chain Acyl-CoA Synthase (ACS(V)L) 
domain132. There has been much debate as to whether the FATPs are true LCFA-
transporters, or if they simply drive cellular FA influx by acylation133,134. Yeast has been 
used as a model since it has one FA transporting FATP-orthologue, and one PM-
associated ACSL. It has been suggested that during evolution, the two yeast-proteins 
have merged into one mammalian FATP protein135. By using yeast strains deficient of 
their endogenous FA transporter, and transfecting them with the mammalian FATPs, it 
was demonstrated that FATP1, FATP2 and FATP4 readily induce FA uptake, whereas 
the other members had weaker activity upon overexpression136. All FATPs except for 
FATP5 could also acylate the FAs. These types of studies could be complemented by 
using combinations of different FATPs, in order to detect enhanced activity through 
heterodimerisation.  
 
Another controversy surrounding the FATPs has been the apparent intracellular 
localisation of FATPs to the Golgi network137 or to the endoplasmic reticulum138. 
Despite of the localisation, the FATPs potently induced NEFA uptake. The use of 
green fluorescent protein fusion proteins and cross-reactive antibodies in these 
studies cannot explain the results completely. It has been proposed that the FATPs 
localize to transport vesicles, which are found intracellularly when the cells are not 
actively taking up LCFAs139. FATP1 and FATP4 have been shown to be transported to 
the PM of adipocytes in response to insulin stimulation139,140. Time-lapse studies of 
different cell types that are stimulated with various NEFAs could be very informative, 
in order to better understand the role and intracellular localisation of all the FATP 
members.  
 
FATP1 has a similar expression pattern as CD36 and is found on white and brown 
adipocytes, myocytes and cardiomyocytes134 (Figure 6). We found FATP1 to be 
expressed by some but not all endothelial cell lines, but not in isolated primary cardiac 
ECs (Paper I). FATP1 requires homodimerisation for proper FA uptake, although this 
might not be unique to FATP1 as dimerisation has not been studied for the other 
FATPs130. One report showed that Fatp1-/- mice had normal weight gain and plasma 
triglycerides, in sharp contrast to Cd36-/- mice141. It further demonstrated that Fatp1-/- 
mice have less intramuscular FAs and greater insulin sensitivity, but only after a 
HFD141. In contrary, a second study reported decreased basal FA uptake in the Fatp1-/- 
mice, and protection against HFD-mediated weight gain140. Fatp1-/- animals also have 
defective thermogenesis in response to cold exposure142. FATP1 is not considered to 
be important in cardiac FA accumulation, but forced cardiac overexpression of FATP1 
results in lipid-induced cardiomyopathy143. In conclusion, FATP1 is a potent FA 
transporter, but the organ-specific roles of FATP1 in FA uptake are still under 
investigation. 
 
FATP2 is expressed in the liver and the kidney86. The protein localises both to 
hepatic peroxisomes and to the PM, and FATP2 has a function within hepatic FA 
transport144. 
 
FATP3 has not been thoroughly studied. Overexpression of FATP3 in yeast showed 
that FATP3 has ACSVL activity, but not FA transporting activity145. Fatp3 is widely 
expressed, including by some endothelial cell lines97. 
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FATP4 has a similar expression pattern as FATP1, but is also expressed in the 
skin134. Three groups independently showed that Fatp4-/- mice die at different stages 
during development or at the latest post-natally due to severe dermal defects146-148. 
The mice have defective formation of the dermal barrier resulting from reduced 
ACSVL activity, and the phenotype is completely rescued by keratinocytic expression 
of FATP4149. Moreover, it has been shown that mutations in Fatp4 can cause an 
inherited skin disease in humans150. The embryonic lethality of the Fatp4-/- mice has 
restricted in vivo research. 
 
FATP5 is the liver-specific FATP, and is expressed post-developmentally on the PM 
of hepatocytes and possibly also in hepatic ECs151. Fatp5-/- mice have decreased hepatic 
lipid uptake and accumulation, but instead shunt lipids to heart, muscle and WAT, and 
the resulting ectopic lipid accumulation led to hyperglycaemia151. Feeding the Fatp5-/- 
mice a HFD led to lower food intake and increased uncoupled thermogenesis, and 
subsequently less weight gain152. The underlying reason might have been defects in 
lipoprotein output from the liver to the WAT151. 
 
FATP6 was described as a heart-specific FATP153, but this has since been disputed134. 
FATP6 readily transports LCFAs, and immunohistochemical localization indicated both 
sarcolemmal and endothelial localization within the heart153. 
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1.3 CURRENT VIEW OF METABOLIC DISEASE AND T2D  
“One of the great ironies of the present-day industrialized world is serious disease and death brought 
about by too much rich food and too little physical exertion”  
Rosen and Spiegelman101 
Over the past 10 years the view of the causes and mechanisms behind T2D and 
metabolic disease has radically changed154. It is only now being recognised that the 
major T2D-preceding event, insulin resistance (IR), is the underlying cause of the 
disease. From being called “a sugar disease” T2D is nowadays considered to be a lipid-
associated disorder, where hyperglycaemia develops as a consequence of IR, and not 
as the cause of T2D5,155,156. Understanding why and how different lipid species influence 
insulin sensitivity is therefore of vital importance. 
 
1.3.1 Pathophysiology of T2D 
Type 1 diabetes (T1D, insulin-dependent or juvenile diabetes metillus) develops when 
the β-cells within the pancreatic islets are attacked and destroyed by the patient’s own 
immune system. T1D is an autoimmune disease whose pathologic origin lies within the 
pancreas, and the disease usually becomes apparent when the patient is fairly young. 
Islet destruction severely decreases insulin production, and without insulin tissues 
cannot efficiently take up glucose. As a consequence, hyperglycaemia develops, and the 
patients need to substitute with exogenous insulin. Poorly managed T1D can lead to 
the development of micro- and macrovascular complications, as well as metabolic 
derangements such as ketoacidosis157. 
 
Type 2 diabetes (T2D, non-insulin dependent or adult-onset diabetes) is currently the 
most common form of diabetes and comprise 95% of diabetes patients158. T2D shares 
most complications with T1D, but the aetiology is very different. In T2D the β-cells of 
the pancreas are initially capable of synthesising and secreting insulin, but the 
peripheral tissues such as liver, muscle, heart and WAT cannot sense and respond to 
the hormone159. This decreased insulin sensitivity deteriorates and subsequently develops 
into total IR. Whereas T1D patients usually are otherwise healthy, T2D is strongly 
associated to obesity and other metabolic diseases (Figure 5). 
 
 
Figure 5. The path to ectopic 
lipid accumulation. 
Nutritional FAs are  taken 
up in the intestine and 
distributed to the working 
tissues (A), and excess 
lipids are stored in the 
WAT (B). An imbalance 
between work and 
nutrition, together with  a 
maximised storage capacity 
in WAT, leads to spill-over 
of FAs from WAT to 
peripheral organs (C).  
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As the peripheral IR increases, several fatal changes occur:  
 
1 Muscle: Decreased insulin sensitivity leads to less glucose uptake. This is 
compensated by increased lipid uptake and oxidative metabolism160.  
2 Pancreas: To compensate for IR in peripheral tissues, the pancreas increases 
insulin production. This leads to pre-diabetes characterized by islet hyperplasia 
and circulating hyperinsulinemia156. The patients become diabetic when the 
peripheral need for insulin exceeds the capacity of the pancreas. The pancreatic 
β-cells cannot sustain high insulin production, and start to deteriorate, whereby 
circulating insulin levels drop. Severe islet deterioration leads to insulin-
dependent T2D156,161.  
3 Plasma: Glucose start to accumulate in the bloodstream. 
4 Liver: Insulin inhibits gluconeogenesis in the liver and increases glycogenesis, 
thereby limiting hepatic glucose output. The liver is usually one of the first 
organs to become IR. Hepatic IR results in continued glucose secretion, which 
further fuels the developing hyperglycaemia162. 
5 WAT: Lipolysis is normally also inhibited by insulin. As a consequence of IR, 
the WAT continues to secrete NEFAs. The NEFAs stay in circulation, and are 
also taken up by the liver. Severe hepatic lipid accumulation can lead to 
triglyceridemias and fatty liver disease. Additionally, insulin-induced TG-uptake 
to the WAT is decreased in IR. 
6 Dyslipidemia. Increased lipolysis from the WAT and decreased adipocyte 
uptake of lipoproteins results in high circulating lipid levels, and contributes to 
the risk of atherosclerotic and other cardiovascular diseases. 
7 Related pathologies: T2D patients have increased risk of cardiovascular 
disease, stroke, amputation, blindness and kidney failure. Most of these 
associated pathologies are common for both T1D and T2D, and their underlying 
molecular mechanisms remain controversial154,163. They will not be further 
discussed within this thesis.  
 
1.3.2 Aetiology of T2D 
IR in multiple organs and cell types lead to the development of T2D. But what causes 
cells to become insulin resistant? Strong evidence suggests that IR is caused by 
excessive lipid accumulation within non-adipose tissues5,156,164 (Figure 5). For example, 
intramyocellular TG content in humans is a determinant of IR165. The infusing of fatty 
acids into lean, healthy subjects acutely impairs glucose uptake5. Various mechanisms 
for how lipids can cause IR have been proposed, and it is unlikely that only one 
mechanism is involved. The list below includes some of the most interesting past and 
present theories.  
 
Contributing factors 
Thrifty genes. Evolution has programmed us to efficiently accumulate all available 
nutrients during times of plenty, meaning we are in constant preparation for periods 
of fasting. The thrifty gene theory, laid out by James Neel almost fifty years ago, 
proposes that some of our more “greedy genes” have today become detrimental, 
causing the metabolic syndrome166,167. Examples are the pro-lipogenic SPREB1c168  and 
the upregulation of FA transporters in response to a HFD160,169. Given today’s 
sedimentary lifestyle, we have not evolved to eat at McDonalds every day.  
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WAT-spill-over effect. Although obesity is strongly associated with T2D, evidence is 
emerging that it is the accumulation of fat outside the WAT that is most damaging156,164. 
This has elegantly been shown in genetic rodent models where the storage capacity of 
the WAT was expanded or restricted164,170. Overexpression of adiponectin in ob/ob 
mice increased the number of adipocytes, leading to WAT hyperplasia170. The 
transgenic mice became overtly obese, while maintaining normoglycaemia.  Restricting 
the storage capacity of each adipocyte in another study resulted in lean, severely 
diabetic mice164. Therefore, a healthy hyperplastic WAT is the safest storage site for 
lipids, protecting peripheral tissues from ectopic lipid accumulation. Overriding the 
storage-capacity for individual adipocytes (hypertrophy) increases lipolysis and spill-
over of the TGs (Figure 5).  
 
WAT inflammation. Obesity has been shown to cause inflammation in the WAT171. This 
has a negative impact on peripheral tissues through increased secretion of pro-
inflammatory cytokines like Tumour Necrosis Factor α, and decreased secretion of 
beneficial adipokines such as adiponectin171. Whether WAT inflammation is a cause or 
consequence of IR within the tissue is still debated172. 
 
Decreased insulin receptor signalling. Several different lipid species have been shown to 
have negative effects on insulin mediated cellular glucose-uptake5. Through the use of 
genetic models, the laboratory of G.I. Shulman has demonstrated the adverse effects 
of diacylglycerols (DAG) on insulin receptor signalling. DAGs are ligands for the novel 
Protein Kinase C (PKC) θ and ε173. Activation of PKC θ alters the phosphorylation 
pattern of the Insulin Receptor Substate 1 (IRS-1), leading to decreased insulin 
receptor signalling. Ceramides, synthesised from saturated FAs, are another type of 
neutral lipid that have been implicated in cellular IR174. The exact pathological 
mechanism of the ceramides is however less well characterized174. 
 
Defective Glut4 vesicle transport. Excess accumulation of lipids in lipid droplets has been 
shown to counteract Glut4-mediated glucose uptake in response to insulin 
signalling175,176. The accumulation of lipid droplets within myocytes traps vesicle fusion 
proteins belonging to the SNARE-family in the cytoplasm177. This directly prevents 
SNARE-mediated fusion of Glut4 vesicles to the PM in response to insulin-stimulation. 
Interestingly, the same proteins have been implicated in the fusion of insulin-filled 
secretion vesicles to the pancreatic PM178. This mechanism could thereby explain the 
pancreatic insulin secretion defect that occurs in response to IR.   
 
Mitochondrial deficiency. The expression of mitochondrial genes is decreased in 
response to a HFD and in diabetic patients179-181. Recently, it was shown that saturated 
FAs can cause epigenetic changes on DNA, which reduce the expression of the 
transcriptional co-regulator PPARγ co-activator 1 α (PGC1α). PGC1α is a master 
regulator of mitochondrial biogenesis, and decreased PGC1α expression leads to 
lower mitochondrial content and thereby less mitochondrial oxidation of lipids182. 
Lower lipid oxidation could further fuel lipid accumulation, leading to a vicious cycle. 
However, it is debated whether mitochondrial dysfunction is a cause or a 
consequence of metabolic disease183.  
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Possible ways to resolve IR 
Increased lipid metabolism. It has been hypothesised that enhancing lipid oxidation in IR-
tissues could induce insulin sensitivity. However, an increase in FA-oxidation would 
also drive the formation of reactive oxygen species (ROS)5. Increased ROS can 
damage cell structures and lead to oxidative stress. Moreover, according to the first 
law of thermodynamics, fat cannot be lost without exercise or work184. The only way 
to oxidise lipids “for free” is by mitochondrial uncoupling, whereby heat is generated 
instead of ATP. Brown adipocytes are specialized at heat generation through 
uncoupling in response to cold, thereby oxidising large quantities of lipids185. 
Therefore, it is hypothesized that a brownification of the WAT, and/or increased lipid 
uptake and oxidation in the BAT, could present a future therapeutic opportunity186.  
 
Decreased muscular FA uptake. Almost all knock-out models of lipid handling proteins 
expressed in the skeletal muscle have increased glucose tolerance116,141,187 (Chapter 2). 
This supports the notion that decreased lipid uptake and accumulation in skeletal and 
cardiac muscles is highly advantagous. The drawback of decreased muscular FA uptake 
is shunting of the lipids to other organs like liver, or increased hypertriglyceridemia 
like the in the Cd36-/- mice (Chapter 2). Ideally, the FA uptake to WAT should be 
increased simultaneously with decreased muscular FA usage. 
 
In conclusion, novel research demonstrates that ectopic lipid accumulation leads to 
various metabolic derangements, although it is not yet agreed upon which cellular 
mechanisms or specific type of lipids cause IR188. Therapeutically the aim is to be able 
to control peripheral lipid accumulation, while shunting excess lipids to BAT for 
oxidation, or to WAT for safe storage. How such a lipid shunting is achieved is 
currently not known. However, if the endothelium has a regulating role in organ-
specific lipid-uptake, this could open up novel opportunities of metabolic control.  
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1.4 VASCULAR METABOLOMICS: THE FUSION OF VASCULAR 
BIOLOGY AND METABOLISM  
 
“During obesity induced by HF feeding, inflammation and insulin resistance develop in the 
vasculature well before these responses are detected in muscle, liver, or adipose tissue.” 
Francis Kim et al 2008172 
 
As described earlier, the vasculature has been widely studied in the context of tissue 
oxygenation2, but not as much for its role in metabolic regulation. Conversely, 
metabolic researchers have often not considered the vasculature as a physiological 
barrier82,83 (Figure 1). Times have changed and a range of novel publications has 
recently addressed the role of the vasculature in different aspects of metabolic 
physiology and pathology.  
 
1.4.1 Endothelial insulin response and IR 
Previously it was believed that insulin induces endothelial permeability, and that the 
resulting increase in local vascular leakage allowed for insulin and nutrients to pass 
through the vascular wall189. Similarly, it has been proposed that FAs, released from 
lipoproteins by LPL, induce local vascular leakage in order to access the PM of the 
parenchymal cells where FA transport proteins are expressed81,190. Nevertheless, 
evidence has emerged that insulin is actively transported through the endothelium, 
and that this transport is the rate-limiting step in muscular glucose uptake191,192. 
 
Insulin-stimulation of ECs induces two major changes to the microvasculature. Firstly, 
insulin increases nitric oxide (NO) production192. NO is a vessel relaxant, which 
dilates the vessels and increases the blood flow through the capillaries. This increase in 
capillary surface area is important for endothelial glucose uptake. Knock-out mice of 
the endothelial NO synthase (eNOS) have reduced glucose uptake and insulin 
sensitivity due to their inability to produce NO in response to insulin193. Secondly, 
insulin also regulates the transport of both itself and nutrients through the ECs191. 
Knock-out mice lacking IRS-2 specifically in ECs have reduced delivery of insulin to 
muscle cells, and significantly decreased glucose uptake. The authors also showed that 
endothelial NO production is regulated through IRS-2-mediated insulin signalling194. 
Based on these results, the endothelium should be added to the list of insulin sensitive 
organs. 
 
Insulin sensitivity is decreased upon excessive lipid exposure (Chapter 3). Recently, it 
was shown that endothelial IR precedes the IR of myocytes. After feeding mice a HFD 
for one week, endothelial Akt phosphorylation and NO production in response to 
insulin were attenuated172. Myocytes and hepatocytes became measurably IR only 
three weeks later, whereas the WAT developed IR even later172. Thus, endothelial IR 
is emerging as a novel component of the metabolic syndrome, joining the ranks of the 
other components listed in section 1.3.1195.  
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1.4.2 Metabolic coupling of the tissue and vasculature 
If metabolite uptake to muscle is regulated at the level of the endothelium and not the 
sarcolemma, how can parenchymal cells assure sufficient nutrient supply to support 
their metabolic needs? Control of nutrient uptake is especially important in light of the 
deleterious effects of excess intra-muscular lipid accumulation (Chapter 3). Thus, 
there must be a communication between tissue cells and the vasculature, coordinating 
energy needs to nutrient uptake. This communication can be called metabolic coupling 
of the vasculature and the surrounding tissue.  
 
LPL is an interesting example of metabolic coupling (Chapter 2). LPL resides on the 
luminal side of the endothelium, where it hydrolyses lipoprotein-associated TGs. 
However, it is not synthesised by ECs, but by parenchymal cells81. LPL is then 
transported through the endothelium to the vascular wall by an EC-specific transport 
protein, glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1)81,196. 
Knock-out of GPIHBPI leads to severe triglyceridemia due to low endothelial-bound 
LPL levels. The trans-endothelial transport of LPL allows for tissue cells to maintain 
transcriptional control of Lpl expression and lipoprotein-hydrolysis, whereas the 
vasculature controls LPL-transport to the vascular wall.  
 
Metabolic coupling of the vasculature to the tissue also helps the working muscle to 
adapt to a specific nutritional need or increased workload. Fasting leads to a rapid 
induction of a complete pro-angiogenic transcription program, including increased 
Vegfa-expression25. This is mediated by PGC1α and the transcription factor Estrogen 
Related Receptor α (ERRα). Similarly, β-adrenergic signalling in response to exercise 
increases PGC1α-levels in skeletal muscle, and leads to VEGF-A synthesis and 
exercise-induced angiogenesis197. Both exercise- and fasting-induced angiogenesis are 
HIF1α-independent, and the authors speculate that physiological angiogenesis could be 
differentially regulated compared to pathological angiogenesis25,197. Cold exposure has 
also been shown to mediate a VEGF-A driven angiogenic program in WAT and BAT, 
which is HIF1α-independent but requires VEGFR2198. It would be very interesting to 
compare the transcriptional and post-transcriptional changes in ECs undergoing 
physiological and pathological angiogenesis.  
 
 
1.4.3 Permeability barrier for nutrient-uptake 
The role and mechanism for vascular LCFA uptake has been poorly studied. Several 
FA handling proteins have previously been indicated to be expressed by the 
endothelium. These include CD36199, FATP13, FATP5151, FATP6153, FABP3200, FABP4126 
and FABP5201. Many reports are regarded as circumstantial by the research field, and 
detailed uptake mechanisms for endothelial FA uptake, and FA transport through the 
endothelium, remains enigmatic3,202. It seems that the expression of Cd36, Fatp1 and 
potentially also Fabp4 is co-regulated (Figure 6B), and these FA handling proteins 
could be cooperating both on the endothelium and on the parenchymal cells (Figure 
6a). 
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Potential mechanism of CD36-mediated FA-uptake. Based on the CD36 literature review 
presented in Chapter 2, a novel hypothesis on the role of CD36 in endothelial FA 
uptake will be described below. Hypothetically, CD36 could be involved in the binding 
and localisation of TG-rich lipoproteins to the vascular wall, so that LPL efficiently can 
hydrolyse them (Figure 6C). CD36 is transported to the PM in response to insulin, 
suggesting a postprandial function110. Lipoproteins have been shown to bind to regions 
rich in lipid rafts81, and CD36 is similarly associated with these regions108. Data from 
publicly available databanks support the endothelial localisation of CD36 in muscle203, 
and shows a strong correlation204 of Cd36-expression with both Lpl- and Gpihbpi-
expression (Figure 6). A role of CD36 in tethering lipoproteins would explain why the 
Cd36-/- mice had elevated TGs instead of elevated NEFAs113, and go well with the 
reported function of CD36 in the clearance of chylomicron89,111 (see Chapter 2). 
Additionally, a recent paper showed CD36 activity to be vital for the uptake of TG-
rich lipoproteins to BAT in response to cold exposure103. This FA handling complex is 
probably found both on the ECs and on the sarcolemmal PM. Hopefully, future 
research will help to confirm or deny this theory, taking us one step closer to a full 
understanding of endothelial lipid uptake.  
 
 
 
VEGF-A and glucose uptake. The endothelium expresses at least two facilitating glucose 
transporters, Glut1 and Glut3, although Glut1 is far better characterized then Glut3205. 
Interestingly, some reports suggest that VEGF-A can upregulate Glut1 expression in 
ECs, at least in the blood-brain barrier206,207. Circulating VEGF-A levels are also 
correlated with lower blood glucose levels in humans208. Positron Emission 
Tomography (PET) measuring 18F-deoxyglucose (18FDG) uptake has been used in the 
clinic to detect glycolytically active tumours and metastasis in cancer patients209. When 
the 18FDG uptake in specific tumours was compared to the expression of Vegfa and 
Vegfb within the tumours, the results showed that glucose uptake correlates positively 
with Vegfa expression and negatively with Vegfb expression209. These results can be 
Figure 6. Hypothetical novel role for CD36. A) Immunohistochemical staining for CD36 in human 
muscle taken from the Human Protein Atlas. Arrow indicates vascular localization. B) Shortened list 
of genes correlating with CD36 in the Sym Atlas database. C) Schematical illustration of the 
hypothesis. CD36 binds to chylomicrons in the circulation, and theters them to the vascular wall so 
that LPL can hydroslyse associated TGs. FATP1 could also belong to this functional unit. 
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explained both in the context of hypoxia-dependent and hypoxia-independent 
regulation of Vegfa expression. Hypoxia is associated with a non-oxidative, glycolytic 
metabolism210. However, during oxidative metabolism glucose is also needed to 
replenish the tricarboxylic (TCA) cycle.  
 
VEGF-A has also been shown to upregulate the expression of Fabp4 in endothelial 
cells in vitro126. This regulation was VEGFR2-dependent, and inhibition of FABP4 
decreased the proliferation of the ECs, suggesting that FABP4 is needed for efficient 
cell division. Similarly, VEGFR1 has been shown to be activated by LDLs, leading to 
endothelial internalization of the lipoprotein and increased cholesterol supply to the 
endothelium211. Both these events have been connected to the need for structural 
lipids and cholesterol in an actively dividing vasculature. 
 
In conclusion, the vasculature is of vital importance not only for deliveries of nutrients 
and oxygen, but also for helping the tissues to control their energy metabolism and 
adapt to physiological changes in their environment. VEGF-A is a potent mediator of 
fasting- and exercise-induced angiogenesis, and VEGF-A signalling to the endothelium 
may upregulate various nutrient transporters. Additionally, PlGF has been implicated 
in adipogenesis, although its roll within the WAT is unclear212-215. Thus, there is an 
emerging role within vascular metabolomics for members of the VEGF-family of 
growth factors.  
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2 AIMS OF THE THESIS WORK 
 
 
 
The biological role of VEGF-B-signalling has remained enigmatic. The starting point of 
this thesis work was bioinformatics showing a strong correlation between the 
expression of nuclear-encoded mitochondrial genes and Vegfb.  
 
The aim of this thesis work was to characterise the biological function of VEGF-B in 
physiology and pathology, with special attention to metabolism.  
 
 
 
The specific aims were: 
 
• To characterize the role of VEGF-B in FA-metabolism, and how 
VEGF-B function is connected to vessel physiology (Paper I). 
 
• To identify endothelial downstream target genes for VEGF-B, and to 
examine the metabolic phenotype of the Vegfb-/- mice (Paper I) 
 
• To study the effects of genetic deletion of VEGF-B in a mouse model 
of T2D (Paper II) 
 
• To investigate if treatment with neutralising antibodies against VEGF-
B could alleviate IR and T2D (Paper II) 
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3 RESULTS AND DISCUSSION  
3.1.1 Paper I: VEGF-B controls fatty acid uptake. 
The biological role of VEGF-B has remained enigmatic, as previous studies of Vegfb-/- 
knock-out mice did not reveal any vascular defects or abnormalities (Chapter 1). We 
therefore used bioinformatics to identify links between VEGF-B and novel signalling 
pathways, metabolic networks or cellular functions (Figure 1a in Paper 1). Genes 
with similar expression patterns were clustered together using a large set of publically 
available microarray data. Surprisingly, Vegfb readily clustered (r = 0.90) with a group 
consisting of only nuclear-encoded mitochondrial genes. Most of these were so-called 
OXPHOS genes179, coding for proteins with functions within the oxidative 
phosphorylation chain, and in particular within Complex I.  
 
We found more evidence supporting the co-regulation of Vegfb and OXPHOS-genes 
(Figure 1b-d). Vegfb is strongly expressed in tissues with a high mitochondrial 
content, such as heart, oxidative skeletal muscle and BAT20. The expression pattern of 
Vegfb is similar to the expression of two markers for the OXPHOS genes, NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex 5 (Ndufa5) and Cytochrome C 
somatic (Cycs). The expression of Vegfb, Ndufa5 and Cycs was equally decreased in 
response to overnight fasting, and increased in response to a HFD. We further 
confirmed the bioinformatics by using the mouse SymAtlas database204 to search for 
genes co-regulated with Vegfb. By using a cut-off of 0.80, we found that only 31 genes 
were co-expressed with Vegfb, whereas many more genes were co-expressed with 
Vegfa and Plgf. The low number of genes suggested that the expression of Vegfb is 
tightly regulated. We further discovered that the co-regulation of Vegfb and OXPHOS 
genes had previously been indicated in a larger study characterising mitochondrial 
proteins216. This provided an independent validation of the results. 
 
The tight co-regulation between the OXPHOS genes and Vegfb stems from 
transcriptional control by ERRα and PGC1α (X.W. and U.E., manuscript in 
preparation). Interestingly, the same transcriptional machinery also regulates the 
expression of Vegfa25. The correlation between Vegfa and mitochondrial genes is much 
weaker (r = 0.30) as compared to Vegfb (Figures 1c and S1). Moreover, Vegfa 
expression is induced by fasting25, whereas fasting seems to reduce Vegfb expression in 
vivo. These differences underline a unique role of Vegfb, but also point out that the 
metabolic regulation of the VEGFs still demands further investigation.  
 
The bioinformatics studies indicated that VEGF-B has a role in energy metabolism. 
Considering that VEGFR1 is only expressed by ECs within tissues19,51,69 (Chapter 1 and 
Figure S10), it suggested that VEGF-B could be helping the vasculature to sense the 
energy status of adjacent parenchymal cells. Hypothetically, higher PGC1α/ERRα 
transcriptional activity would lead to coordination of mitochondrial biogenesis and 
VEGF-B secretion, which would be sensed by ECs through the signalling of VEGFR1. 
The model became complete when we found that the downstream endothelial 
effectors were members of the FATP family (Chapter 2 and Figure 7). 
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Many aspects of FATP biology were unknown (see Chapter 2). Which of the FATPs, if 
any, were expressed by the endothelium in vivo? Could all FATPs facilitate LCFA 
transport? Were the vascular FATPs required for endothelial LCFA uptake and 
transport?  
 
We found that VEGF-B signalling through VEGFR1 and NRP1 on ECs could control 
the transcription of specific FATPs both in vitro and in vivo (Figures 2-3). The change 
in relative mRNA expression of each FATP was modest, around 2.5-3 fold, which was 
reflected by a similar change in in vitro LCFA uptake upon VEGF-B stimulation. 
However, the siRNA experiments confirmed that the FATPs were necessary and 
sufficient for LCFA uptake in vitro. In terms of which of the FATPs was the most 
important for FA transport regulated by VEGF-B, the results pointed towards FATP3. 
The expression of Fatp3 was dependent of VEGF-B signalling in all tested cell lines, 
tissues and animal models except for in the lung (Figure 2, S4, S5 and S9). 
Although Fatp3 is expressed at low levels, its expression seems to be specific to the 
vasculature. We showed for the first time that FATP3 required co-expression with 
FATP4 in order to be fully active (Figure 3d). Homodimerisation has been reported 
for FATP1 (Chapter 2), making the necessity for FATP3/FATP4 heterodimers an 
interesting hypothesis. This could be one of the reasons why FATP3 has not 
previously been considered to facilitate FA uptake145.  
 
The tissue and cell specificity of VEGF-B/FATP-regulated LCFA uptake is very 
interesting (Figure 3, S6, S11 and S16). The lack of effect of VEGF-B signalling in 
isolated primary cardiomyocytes and brown adipocytes, as well as in cultured HL-1 
cardiomyocytes is most probably due to that the cells lack VEGFR145. However, 
treatment with VEGF-B did not induce transcription of Fatp4 in VEGFR1-expressing 
NIH3T3 fibroblasts. Moreover, we found no transcriptional changes of Fatp3 in 
isolated primary lung ECs or in the small intestine from Vegfb-/- mice. Similarly, another 
research group failed to find changes in the transcription of FATPs in the pancreas of 
transgenic mice overexpressing VEGF-B specifically in the pancreatic β-cells217. Possibly 
we have yet to identify some critical component for VEGF-B/FATP function 
downstream of VEGFR1, which has a restricted expression pattern that varies 
between different vascular beds.  
Figure 7. Schematic summery of 
Paper I featured in NEJM 2010. In 
Panel A, VEGF-B mediates FA-
uptake through transcriptional 
regulation of FATPs. In panel B, 
FAs are instead shunted to 
WAT when VEGF-B is missing. 
Reproduced with permission of 
the publisher. 
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We currently believe that FATP transcription cannot be the only pathway for vascular 
LCFA uptake controlled by VEGF-B (A.F. and U.E., unpublished data), and ongoing 
research aims to identify additional transcriptional or post-transcriptional 
components. The FA uptake phenotype of Vegfb-/- mice seems more robust than the 
modest changes in FATP transcription, supporting additional mechanisms. A re-
examination of the metabolic needs and preferences of different tissues, as well as 
further research of how such a preference is controlled, would be highly interesting. 
 
We confirmed the novel role of VEGF-B in vivo by examining the metabolic phenotype 
of Vegfb-/- mice (Figure 4). To measure organ-specific LCFA uptake we fed the mice 
14C-labeled oleic acid by oral gavage. However, there are some drawbacks with this 
method.  It does not allow for examination of the intracellular destination within an 
organ. It is also difficult to show whether VEGF-B-mediated uptake is more important 
for chylomicron-, VLDL- or albumin-bound lipids. Cellular β-oxidation will not damage 
the radioactive labelling, but entry into the TCA cycle will rapidly transfer 14C to CO2, 
making detection of FA uptake impossible after exhalation. One would therefore like 
to develop new methods using more sensitive and specific labels, as was recently done 
in one study103.  
 
The oral gavage experiments showed that the labelled LCFAs in Vegfb-/- mice 
accumulated in various WAT depots after 24 hours. The Vegfb-/- mice gained more 
weight with age, and their increased adiposity was confirmed by magnetic resonance 
imaging. The shunting of FA uptake to WAT should be beneficial for whole body 
metabolism, but normally lead to undesired hypertrophy (Cahpter 3). Surprisingly, the 
adipocytes of the Vegfb-/- mice were instead hyperplastic (A.M. and U.E., manuscript in 
preparation). The molecular mechanisms behind increased lipid accumulation and 
hyperplasia in Vegfb-/- WAT are still unknown. No major differences in WAT Fatp3 and 
Fatp4 expression were detected, but Fatp1 expression was increased in Vegfb-/- WAT 
(A.M. and U.E., unpublished data). Adiponectin was not changed170. Ongoing research 
includes using metabolic cages to examine eating behaviour, activity and the 
respiratory quotient of the Vegfb-/- mice, in order to build a complete picture of the 
factors influencing weight gain.  
 
To confirm that the decreased muscular LCFA uptake in Vegfb-/- mice had an impact 
on lipid accumulation, we used Oil Red-O (ORO) staining of frozen tissue sections 
(Figure 4e-g). ORO is a classical method that stains neutral lipids within tissues, but 
does not detect biological membranes218. However, this method is not without 
disadvantages. It is tedious and requires analysis of multiple microscopic frames. The 
ORO staining can vary considerably between different regions of an organ. 
Additionally, it unspecifically stains all neutral lipids, not distinguishing between 
different lipid species. FATPs have been shown to have the highest affinity for different 
types of LCFAs. In our in vitro assays we used 4,4-difluoro-5-methyl-4-bora-3a,4a-
diaza-S-indacene-3-dodecanoic acid (BODIPY-FA), a saturated 16-carbon LCFA 
mimic, and oleic acid, an 18:1-unsaturated FA. Alitalo and co-workers reported 
accumulation of ceramides, synthesised from saturated FAs, in the hearts of transgenic 
mice with cardiac-specific VEGF-B overexpression47. It would therefore be interesting 
to discover if the VEGF-B/FATP system has a preference for saturated LCFAs, and if 
this could explain the beneficial effects of targeting VEGF-B (Paper II). Given the  
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recent advances in technology, large-scale metabolomics using HPLC/MS or magnetic 
resonance spectroscopy to investigate intra-muscular lipid accumulation would be the 
most appropriate method to assay for lipid accumulation within Vegfb-/- tissues. We 
hope that such technology in the future will help us to identify what kind of lipids the 
VEGF-B/FATP system transports.  
 
Lastly, the results should be discussed in the context of VEGF biology (Figure 2). 
The bioinformatics and in vitro cell culture experiments suggested that the role of 
VEGF-B in oxidative metabolism is unique and different from the other VEGFR ligands. 
Importantly, experiments done by us and others45 using neutralising antibodies against 
VEGF receptors showed that inhibiting VEGFR2 has no effect on VEGF-B signalling. 
This is in contrast to part of the angiogenic affect by PlGF with is mediated by 
displacing VEGFR1-bound VEGF-A (Figure 3). The FATPs provide a novel target gene 
downstream of VEGFR1 signalling since VEGFR1-TK-/- mice had reduced cardiac FATP 
expression. Identification of the FATPs will permit assays where PlGF- and VEGF-B-
dependent activity can be monitored and separated. We addressed the ligand 
redundancy by adding a 10x excess of PlGF together with VEGF-B186, but there was no 
change in VEGF-B signalling. This occurred despite the protein’s ability to bind to the 
same domain of the receptor15,18. It suggests that the two VEGFR1-specific ligands 
VEGF-B and PlGF recognise individual epitopes on the receptors, or the involvement 
of an additional co-receptor. Additionally our results show that proper signalling by 
the VEGFR1 intracellular domain is required for adult physiological FA uptake.  
 
In conclusion we report an unexpected and novel role for VEGF-B in controlling 
vascular LCFA transport. This role is specific for VEGF-B within the VEGF family of 
growth factors, and requires proper function and endothelial expression of VEGFR1 
and NRP1. VEGF-B signalling to ECs induces transcriptional upregulation of members 
of the FATPs, most notably Fatp3. This leads to transport of LCFAs across the 
vascular barrier in a manner proportional to FATP expression. As a consequence, 
Vegfb-/- mice and NRP1-EC-/- mice have lower cardiac accumulation of neutral lipids. 
We could further show that Vegfb-/- mice instead have higher mobilisation of glucose 
uptake into their hearts, suggesting a compensatory switch in metabolism. The co-
regulation of a vascular growth factor with OXPHOS genes suggests a novel 
regulatory mechanism that exists to keep working muscle supplied with adequate 
amounts of nutrients (Figure 8). Thus, VEGF-B has a role in metabolic coupling of the 
tissue cells and the endothelium. 
 
 
Figure 8. Schematic illustration on the role of VEGF-B: 
I) VEGF-B is co-expressed with mitochondrial 
proteins in order to coordinate lipid uptake and β- 
oxidation. II) VEGF-B signals in a paracrine fashion 
to endothelial VEGFR1 and NRP-1. III) Stimulation 
of ECs with VEGF-B upregulates vascular FATPs, 
and (IV) subsequent transport of LCFAs across 
the EC layer. 
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3.1.2 Paper II: Targeting VEGF-B in IR and T2D 
 
 
IR, T2D and its complications are becoming an increasing health problem 
worldwide158. Lifestyle changes are still by far the most effective treatment for T2D219. 
It is now recognised that IR and intra-myocellular lipids are the major underlying 
causes for the development of T2D-associated pathologies (Chapter 3). Although the 
precise cellular mechanism and the type of lipids are not agreed upon by the field, it is 
clear that intra-myocellular lipids should be targeted in both pre-diabetic and diabetic 
subjects5.  
 
With this background, we asked whether targeting the VEGF-B/FATP axis could 
decrease intra-myocellular lipid accumulation in a pathological context as well. We 
aimed to study this by genetically deleting Vegfb and by targeting VEGF-B 
therapeutically using a neutralising antibody treatment. As an animal model, we chose 
to use the db/db mouse, which is on of the most well-characterised and severe animal 
model of T2D presently available220.  
 
The lack of co-regulation between Vegfb and mitochondrial OXPHOS genes in db/db 
mice raised many interesting questions (Figure 1). Mitochondrial content is reduced 
in response to obesity, IR and T2D180 (Chapter 3). In line with this, we found reduced 
cardiac expression of Ndufa5 and Cycs in the diabetic db/db mice as compared to 
healthy db/+ controls. To our surprise, the expression of Vegfb as well as Fatp3 was 
not reduced in the diabetic mice. Similarly it has been proposed that obese men have 
higher circulating VEGF-B levels as compared to lean men221. However, questions 
remain as to whether this dysregulation between Vegfb and OXPHOS expression is 
specific for db/db mice, wheter it can be found in other diabetic models, and most 
importantly in diabetic patients. It does correlate well with the induction of Cd36 and 
Fatp1 expression in response to T2D98,222. The regulatory mechanism remains 
unknown, although epigenetic changes could be involved (Chapter 3). Thus, future 
research will have to clarify how Vegfb expression is regulated in response to a HFD, 
IR and T2D.  
 
To study how genetic deletion of Vegfb affected the development of T2D in db/db 
mice, we crossed them with Vegfb-/- mice (Figure 2-3). We found that in contrast to 
db/db controls, db/db//Vegfb-/- and db/db//Vegfb+/- mice did not develop hyperglycaemia, 
and they maintained weight gain throughout the study. We confirmed that the 
heterozygous db/db//Vegfb+/- mice maintained the expected level of Vegfb expression in 
the heart. It will be interesting to complete these results with similar analyses of other 
organs, most notably skeletal muscle. The reason for the heterozygous db/db//Vegfb+/- 
mice having such a strong phenotype thus remains unknown. Heterozygous Vegfa+/- 
and Vegfc+/- mice also have phenotypes15 (Chapter 1). It might therefore be common 
for all VEGFs that tight expressional regulation is essential.  
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We next analysed the overall cardiac metabolism of the db/db//Vegfb-/- mice (Figure 
2). Db/db//Vegfb+/- and db/db//Vegfb-/- mice have reduced Fatp3 levels in the heart, and  
ORO staining showed reduced cardiac lipid accumulation upon Vegfb deletion. PET 
analyses showed that db/db//Vegfb-/- mice have increased basal cardiac glucose uptake. 
We confirmed these results by measuring total 18FDG radioactivity in isolated skeletal 
muscles and hearts using a dose calibrator. An identical increase in 18FDG radioactivity 
in both hearts and muscles from db/db//Vegfb-/- mice suggested that the phenotype of 
skeletal muscle is similar to that of heart, in accordance to what we found in Paper I. 
Although we have focused most experiments on the heart, future research will include 
further analyses of skeletal muscle, liver and pancreatic functions.  
 
Total deletion of VEGF-B in the db/db mice was also associated with previously 
unidentified defects. The db/db//Vegfb-/- mice are very nervous and stressed, especially 
upon fasting. Handling of fasted animals, for example giving a sham PBS injection to a 
fasted db/db//Vegfb-/- mouse, acutely raised its blood glucose levels, whereas it did 
nothing to db/db controls or lean wt mice. The heterozygous db/db//Vegfb+/- mice have 
a more subtle stress response, and we have not observed any stress symptoms in 
animals treated with the anti-VEGF-B antibody 2H10. Presently, we believe that this is 
connected to some previously unknown developmental defects due to Vegfb deletion. 
It could potentially be associated with the anti-apoptotic role of VEGF-B on neuronal 
cells52,53. However, the glucose-liberating phenotype suggests increased cortisol 
secretion and/or sensitivity.  
 
The glucose tolerance tests (GTT) and insulin tolerance tests on the db/db//Vegfb-/- 
mice showed that the mice have increased glucose tolerance and insulin sensitivity as 
compared to db/db mice (Figure 3). Enhanced glucose clearance during the GTT 
further suggested that mice lacking Vegfb maintain better pancreatic islet function, 
although we found no difference in basal insulin levels. Measurement of insulin 
secretion during the GTT would be highly informative. During the GTT, the blood 
glucose of  the db/db//Vegfb-/- mice initially rose abnormally high, and several reasons 
for this could be plausible. IR might persist in the liver or in the WAT, where Vegfb is 
not highly expressed. The abnormal stress response could also be an influence. Future 
plans include analysing IRS-1 phosphorylation levels in various organs in order to 
characterise organ-specific IR.  
 
To study the potential of VEGF-B as a therapeutic target, we took advantage of the 
previously described monoclonal antibody 2H10 (Figure 4-5). 2H10 was shown to 
have high affinity specifically for VEGF-B223, and in Paper I we demonstrated that 2H10 
prevented VEGF-B-mediated upregulation of FATPs in vitro. We have now shown that 
treatment of db/db animals with 2H10 for 10 weeks reduces cardiac Fatp3 mRNA 
expression and lipid accumulation as visualised by ORO staining. Furthermore, 2H10-
treatment of either pre-diabetic or diabetic db/db mice has clear anti-diabetic effects, 
suggesting that the antibody is able to traverse the vascular wall and neutralise VEGF-
B found on the interstitial side. This is also in line with the results from Paper I 
showing acutely increased intra-cardiac lipid levels after adenoviral VEGF-B 
administration. Moreover, the finding that the heterozygous db/db//Vegfb+/- mice have a 
strong phenotype might explain the observed rigid response to antibody treatment.  
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The pre-diabetic mice treated with 2H10 did not develop hyperglycaemia, and had a 
normal GTT response at the end of the treatment period (Figure 4). The already 
diabetic mice receiving 2H10 showed a significant reduction in blood glucose levels as 
compared to controls and had enhanced glucose tolerance (Figure 5). Interestingly, 
neither of the 2H10 treatments resulted in a significant gain of body weight. We have 
not yet measured energy expenditure, activity and food intake in db/db mice treated 
with 2H10. Food intake is a critical factor when using a mouse model that has a 
targeted disruption of the leptin pathway.  
 
Finally we analysed metabolic plasma parameters in the transgenic and antibody-
treated db/db mice (Figure 3-5). The db/db//Vegfb-/- mice as well as the pre-diabetic 
2H10-treated animals had reduced circulating levels of plasma NEFAs, TGs, ketones 
and low-density lipoprotein-associated cholesterol. The change in metabolic plasma 
parameters was as expected milder in the diabetic db/db mice receiving 2H10 as 
compared to the pre-diabetic mice, but still showed the same tendency. This suggests 
that reducing peripheral IR has positive effects on dyslipidemia and ketogenesis. The 
reduced levels of NEFAs might be due to the increased anti-lipolytic effect of insulin 
on WAT. This would also reduce the hepatic lipid accumulation, possibly leading to 
decreased synthesis of VLDL and cholesterol. Insulin signalling also inhibits 
ketogenesis, suggesting increased hepatic insulin sensitivity in response to 2H10 
treatment. Taken together, the above assumptions might explain the significant 
changes in plasma metabolites. However, peripheral insulin sensitivity in specific 
organs has to be validated by analysis of organ-specific phosphorylation patterns and 
metabolism. 
 
In conclusion we show that VEGF-B has the potential to be a novel target in the 
treatment of peripheral IR and T2D. We show that acute and genetic inhibition of 
VEGF-B signalling has significant anti-diabetic effects. Furthermore, 2H10 treatment 
also has profound effects on circulating metabolites, and leads to reduced 
triglyceridemia and ketosis. We therefore propose that inhibition of VEGF-B signalling 
is a novel exciting treatment option against IR and T2D.  
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4 FUTURE PERSPECTIVES  
The studies included in this thesis will hopefully be the exciting starting points of much 
research to come. Some key questions are listed below. 
 
Paper I contributed to the VEGF field by describing a novel metabolic role for a VEGF. 
Paper I also further connects FA uptake to tissue oxygenation by showing that growth 
factors of the same family can facilitate these two key events. Many interesting 
questions remain. It is still not known how the ligand-specific effects are mediated 
within the VEGF family. The discovery of a way to assay for VEGF-B signalling will 
facilitate further research on this topic. There exists many unknown intracellular steps 
downstream of VEGFR1 and NRP1 signalling. Furthermore, one should explore 
additional connections between the metabolic functions of VEGF-A and VEGF-B. Both 
VEGFs are regulated by the same metabolic transcription program including PGC1α 
and ERRα (Chapter 4). However, VEGF-A is also regulated by hypoxia, and can 
possibly induce glucose uptake. Clearly there are some interesting vascular 
metabolomics questions yet to be answered. 
 
Secondly, Paper I and II both highlight the role of the vasculature as a potent barrier 
for nutrient uptake, and hopefully this will lead to more research exploring this topic 
(Chapter 4). What is the source of the lipids that are transported through the VEGF-
B/FATP system, i.e. are they derived from lipoproteins and/or lipolysis or both? What 
is the role of the FATPs within ECs, and what is the transport route through the 
endothelium? Do perivascular cells such as pericytes or smooth vascular cells also 
contribute to nutrient uptake? Is glucose uptake regulated at the level of the 
vasculature in muscular tissues? Some recent results suggest this (Chapter 4). 
Additionally a re-evaluation of lipid transport over the blood-brain-barrier would be 
very interesting. Looking at these seemingly metabolic questions from a vascular 
perspective will hopefully produce much interesting research in the future. 
 
Finally, it is clear that the results presented in Paper II are exiting and should be 
further expanded. The study still lacks some supporting evidence, such as 
measurement of the insulin sensitivity in individual organs and detailed characterisation 
of the role of VEGF-B in pancreatic function. In a long-term perspective, these results 
will be repeated in other animal models, and the toxicology of 2H10 should be 
investigated, hopefully in preparation for moving into pre-clinical trials. We are 
currently also working on a more complete phenotypic description of the Vegfb-/- 
mice, which will help to decipher developmental defects of VEGF-B-inhibition from 
acute effects. Thus research into the role of VEGF-B in fatty acid uptake and metabolic 
disease has only started, and hopefully we have managed to contribute to the 
emerging field of vascular metabolomics!   
 
Lastly I would like to thank all of you who have actually read through this thesis, for 
your admirable interest and sincere dedication. 
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